Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
DiagnosTear Technologies, Inc. ( (TSE:DTR) ) has shared an announcement.
DiagnosTear Technologies Inc. has announced that their TeaRx™ diagnostic tool for Dry Eye Syndrome will be featured in a presentation at the ARVO 2025 Annual Meeting. The study, conducted at the LV Prasad Eye Institute, demonstrated that TeaRx™ can effectively diagnose various severities of Dry Eye Syndrome, including identifying severe Meibomian Gland Dysfunction, with significant accuracy. Additionally, the tool showed promising results in predicting therapeutic responses to Cyclosporin A therapy, offering a non-invasive method to improve treatment selection for patients.
More about DiagnosTear Technologies, Inc.
DiagnosTear Technologies Inc. is a leader in developing innovative point-of-care diagnostic solutions for eye diseases. The company focuses on products that enhance the diagnosis and management of eye conditions, particularly through their pioneering TeaRx™ diagnostic tool for Dry Eye Syndrome.
YTD Price Performance: -11.76%
Average Trading Volume: 14,078
For detailed information about DTR stock, go to TipRanks’ Stock Analysis page.